Fenwick Represents Neoleukin in Merger Agreement with Neurogene

Fenwick is representing Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) in its definitive merger agreement with Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases.

The combined company will focus on advancing Neurogene’s pipeline of differentiated genetic medicines, including NGN-401, a clinical-stage product for Rett syndrome, which uses novel gene regulation technology for a potential best-in-class profile. Upon completion of the merger, the combined company is expected to operate under the name Neurogene Inc. and trade on the Nasdaq Capital Market under the ticker symbol “NGNE”. The transaction is expected to close in the fourth quarter of 2023, subject to customary closing conditions and approval by Neurogene and Neoleukin stockholders. More information can be obtained from Neoleukin’s announcement.

The Fenwick transaction team included corporate partner David Michaels, counsel Jeremy Delman and associates Min Ju Park and Matt Reiser; capital markets partners Robert Freedman and Julia Forbess, counsel Chelsea Anderson and associates Tyler Gratton, John Clancy and Teresa Anselmo; executive compensation and employee benefits partner Elizabeth Gartland and counsel Laura Mclntyre; and tax partner Mike Knobler and associate Daphny Lazarus.